Dyne Therapeutics, Inc.
$17.99
-3.4%Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.2).
Valuation inputs: P/E -5.2, earnings yield N/A, momentum -3.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -45.9%, ROIC -41.0%).
Profitability stack: net margin 0.0%, ROE -45.9%, ROIC -41.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +18.1%, momentum -3.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Dyne Therapeutics, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Dyne Therapeutics, Inc. Fair Value Envelope
Dyne Therapeutics, Inc. Profit Bridge
Profitability Analysis
Dyne Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Dyne Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Dyne Therapeutics, Inc. Street Expectations Map
Wall Street analysts project that DYN stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 37.40, with estimates ranging from a low of 23.00 to a high of 60.00.
The consensus 1-year price target stands at 37.40, with estimates ranging from a low of 23.00 to a high of 60.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High uncertainty. Very wide target spread indicates significant disagreement among analysts—major valuation uncertainty or transformation underway.
Analyst Conviction
High uncertainty: Wide dispersion indicates analysts struggle to agree on valuation—proceed with caution and independent analysis.
Market Sentiment Insight
High risk, high reward: Substantial upside potential exists, but wide analyst disagreement signals execution risk or unclear catalysts. Thorough due diligence essential before committing capital.
Dyne Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.11M and sold $23.94M worth of DYN shares, resulting in $22.84M of net selling activity.
3 Months
11.5K
197.26K
1.2M
23.63M
-23.4M
-$23.43M
3-6 Months
0
0.00
3.8K
56.38K
-56K
-$56K
6-9 Months
0
0.00
3.7K
76.37K
-76K
-$76K
9-12 Months
100.0K
911.00K
13.7K
182.10K
+729K
+$729K
Top Buyers
Cox John
Director, Officer: Ceo & President
$911K
Posner Brian S
Director
$197K
Top Sellers
Kersten Dirk
Director
$14.56M
Rhodes Jason P
Director
$8.84M
Cox John
Director, Officer: Ceo & President
$246K
Kerr Douglas
Officer: Chief Medical Officer
$137K
Lucera Erick
Officer: Chief Financial Officer
$133K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $22.84M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 2 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
No Dividend Yield Data
DYN has not reported any dividend yield values in the available annual periods.
dyn Dividend History
Learning Layer
Related Guides
Build conviction on DYN by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.